IP Library › Granted Patent US 12,264,415
Granted Patent B2
US 12,264,415 · App. 18/459,805 · Granted Apr 1, 2025

Polycaprolactone-based fibers and implants including same

Inventors: Bhavin B. Shah (West Lafayette, IN); Benjamin Patrick Kline (Lafayette, IN); Rhonda Peck (West Lafayette, IN)
Assignee: Cook Biotech Incorporated
D01F6/625A61L27/18A61L29/06A61L31/06D02J1/20D10B2331/041D10B2401/061D10B2509/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,264,415
App. No.
18/459,805
Granted
Apr 1, 2025
Kind
B2
Abstract

A polymeric material fiber includes a polymeric material which is a homopolymer of caprolactone or a copolymer of at least 90% by weight of caprolactone and one or more additional monomers. An implantable mesh includes this fiber alone or combined with one or more additional fiber materials. Methods for treating patients involve implanting the fiber material, for example incorporated in a mesh.

Claims (28)

1. A melt extruded, oriented polymeric material fiber, wherein the polymeric material is a homopolymer of caprolactone or a copolymer of at least 90% by weight of caprolactone and one or more additional monomers; and wherein:

(i) the polymeric material fiber has a tensile strength of about 450 MPa to about 650 MPa; and

(ii) the polymeric material fiber has an elongation at break in the range of 45% to 65%.

2. The melt extruded, oriented polymeric material fiber of claim 1 , wherein the polymeric material has been stress hardened by stretching.

3. The melt extruded, oriented polymeric material fiber of claim 1 , wherein the polymeric material fiber has an elastic modulus in the range of 750 MPa to 1200 MPa.

4. The melt extruded, oriented polymeric material fiber of claim 1 , wherein the polymeric material fiber has a tensile strength in the range of about 500 MPa to about 650 MPa.

5. The melt extruded, oriented polymeric material fiber of claim 1 , which has been prepared by a method comprising melt extruding the polymeric material to form an extrudate, allowing the extrudate dwell time to crystallize, and drawing the extrudate.

6. The melt extruded, oriented polymeric material fiber of claim 1 , wherein the polymeric material fiber has an average diameter in the range of about 0.01 to about 0.4 mm.

7. The melt extruded, oriented polymeric material fiber of claim 1 , wherein the polymeric material fiber has a crystallinity in the range of 35% to 50%.

8. The melt extruded, oriented polymeric material fiber of claim 1 , wherein the homopolymer or the copolymer is a linear polymer.

9. The melt extruded, oriented polymeric material fiber of claim 1 , wherein the tensile strength of the fiber, as measured after immersion in phosphate buffered physiological saline for 60 minutes, decreases less than 20% after immersion in phosphate buffered physiological saline for 6 months.

10. The melt extruded, oriented polymeric material fiber of claim 1 , wherein the polymeric material is a homopolymer of caprolactone.

11. The melt extruded, oriented polymeric material fiber of claim 1 , wherein the polymeric material is a copolymer of at least 90% by weight of caprolactone and one or more additional monomers.

12. The melt extruded, oriented polymeric material fiber of claim 1 , wherein the number average molecular weight of the homopolymer or the copolymer is in the range of about 10000 to about 150000 kDa.

13. The melt extruded, oriented polymeric material fiber of claim 1 , which has been sterilized.

14. A medical device comprising one or more melt extruded, oriented polymeric fibers according to claim 1 .

15. The medical device of claim 14 , wherein the device is a medical textile, tube, surgical mesh, hernia mesh, breast reconstruction mesh, mastopexy mesh, pericardial patch, anti-adhesion patch, cardiovascular patch, guided tissue regeneration patch, sling, monofilament suture, multifilament suture, ligament repair device, tendon repair device, meniscus repair device, cartilage repair device, nerve guide, stent, vascular graft, or dura repair device.

16. A medical device according to claim 15 , further comprising a decellularized extracellular matrix tissue.

17. A method for making a melt extruded, oriented polymeric material fiber, comprising:

melt extruding a polymeric material which is a homopolymer of caprolactone or a copolymer of at least 90% by weight of caprolactone and one or more additional monomers, to form an extrudate;

solidifying the extrudate by cooling the polymeric material; and

drawing the extrudate so as to stretch harden the polymeric material, wherein the polymeric material fiber has a tensile strength of about 450 MPa to about 650 MPa, and the polymeric material fiber has an elongation at break in the range of 45% to 65%.

18. The method of claim 17 , wherein said drawing elongates the extrudate by at least 600%.

19. An implantable medical mesh product, comprising:

a mesh structure comprised of woven and/or knit fibers, wherein the fibers include at least one melt extruded, oriented polymeric material fiber, wherein the polymeric material is a homopolymer of caprolactone or a copolymer of at least 90% by weight of caprolactone and one or more additional monomers; and

wherein the polymeric material fiber has a tensile strength of about 450 MPa to about 650 MPa, and the polymeric material fiber has an elongation at break in the range of 45% to 65%.

20. The implantable medical mesh product of claim 19 , wherein the mesh structure is connected to at least one sheet of a decellularized extracellular matrix tissue.

21. The implantable medical mesh product of claim 19 , wherein the mesh structure is sandwiched between a first sheet of extracellular matrix tissue and a second sheet of extracellular matrix tissue.

Assignments (4)
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS AND TRADEMARKS Recorded Sep 25, 2025
From: ARES CAPITAL CORPORATION
To: COOK BIOTECH INCORPORATED
Reel/Frame 072938/0231 →
SECURITY INTEREST Recorded Sep 25, 2025
From: RTI SURGICAL, INC.; COOK BIOTECH INCORPORATED; TISSX, LLC
To: GOLUB CAPITAL MARKETS LLC, AS COLLATERAL AGENT
Reel/Frame 072924/0721 →
SECURITY INTEREST Recorded Apr 3, 2024
From: COOK BIOTECH INCORPORATED
To: ARES CAPITAL CORPORATION, AS SECURITY AGENT
Reel/Frame 067001/0541 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 4, 2023
From: SHAH, BHAVIN B.; KLINE, BENJAMIN PATRICK; PECK, RHONDA
To: COOK BIOTECH INCORPORATED
Reel/Frame 065117/0319 →
Continuity (3)
Continuation 16893777 · Jun 5, 2020
Provisional Application 62858560 · Jun 7, 2019
Related Publication 20240068131A1 · Feb 29, 2024
References Cited (30)
US 3361859A · Cenzato · 1968 [cited by applicant]
US 4190720A · Shalaby · 1980 [cited by examiner]
US 11746443B1 · Shah · 2023 [cited by examiner]
US 20080061467A1 · Iwata et al. · 2008 [cited by applicant]
Kim et al., (“Surface Modification of Melt Extruded Poly(-caprolactone) Nanofibers: Toward a New Biomaterial Scaffold” in ACS Macro Letters, Jun. 6, 2014). (Year: 2014). [cited by examiner]
Azimi et al., “Poly(-caprolactone) Fiber: An Overview” in Journal of Engineered Fibers, vol. 9, Issue 3, 2014, pp. 74-90. (Year: 2014). [cited by examiner]
Molloy et al. “Factors influencing the small-scale melt spinning of poly(-caprolactone) monofilament fibers” in Polymer International, vol. 52, pp. 1175-1181, 2003. (Year: 2003). [cited by examiner]
Gisela C. C. Mendes et al., “Ethylene oxide sterilization of medical devices: A review,” in American Journal of Infectious Control, Nov. 2007; 35(9):574-581 (Year: 2007). [cited by examiner]
“A study of the impact of ethylene oxide sterilizing modes on properties of glycolactic sutures”. Tomsk State University Journel, 2014 No. 3. [cited by applicant]
Abedalwafa et al. “Biodegradable Poly-Epsilon-Caprolactone (PCL) for Tissue Engineering Applications: A Review”, Rev. Adv. Mater. Sci. 34 (2013), pp. 123-140. [cited by applicant]
Azimi et al. “Poly (e-caprolactone) Fider: An Overview”, Journal of Engineered Fibers and Fabrics, vol. 9, Issue 3, 2014. [cited by applicant]
Baylon et al. “Past, Present and Future of Surgical Meshes: A Review”, Membranes 2017, 4, 47. [cited by applicant]
Catanzano et al., “Melt-spun bioactive sutures containing nanohybrids for local delivery of Anti-inflammatory drugs”, Materials Science and Engineering C 43 (2014) pp. 300-309. [cited by applicant]
Chu “Materials for absorbable and nonabsorbable surgical sutures”, Biotextiles as Medical Implants, 2013, 1 pg. [cited by applicant]
Deeken et al. “Characterization of the Mechanical Strength, Resorption Properties, and Histologic Characteristics of a Fully Absorbable Material (Poly-4-hydroxybutyrate—PHASIX Mesh) in a Procine Model of Hernia Repair”,… [cited by applicant]
Gardyne et al. “The application of co-melt-extruded poly(e-caprolactone) as a controlled release drug Delivery device when combined with novel bioactive drug candidates: Membrane permeation and Hanson dissolution studie… [cited by applicant]
Haji et al. “The Effect of Hot Multistage Drawing on Molecular Structure and Optical Properties of Polyethylene Terephthalate Fibers”, Material Research, 2012; 15(4): 554-560. [cited by applicant]
Hayashi et al. “Studies on Biodegradable Poly(Hexano-6-Lactone) Fibers. Part 3. Enzymatic Degradation in Vitro”, Pure Appl. Chem., vol. 74, No. 5, pp. 869-880, 2002. [cited by applicant]
Kaffashi, et al. “Poly(e-caprolactone)/triclosan loaded polylactic acid nanoparticles composite: A Long-term antibacterial bionanocomposite with sustained release”. International Journal of Pharmaceuticals, vol. 508, is… [cited by applicant]
Kim, S. E., et al. “Surface modification of melt extruded poly(-caprolactone) nanofibers: Toward a new Biomaterial scaffold”. ACS Publications, vol. 3, issue 6, (2014), pp. 585-589. Retrieved from the Internet, DOI < 10… [cited by applicant]
La Mantia et al. “Effect of cold drawing on mechanical properties of biodegradable fibers”, J. Appl. Biomater Funct Mater 2017, 15(1): e70-e76. [cited by applicant]
Mendes, G. C. C., et al. “Ethylene oxide sterilization of medical devices: A review”. American Journal of Infectious Control, vol. 35, issue 9, (Nov. 2007), pp. 574-581. Retrieved from the internet, DOI. < 10.1016/j.aji… [cited by applicant]
Mochizuki et al. Studies on Biodegradable Poly(Hexano-6-Lactone) Fibers 1. Structure and Properties of Drawn Poly (Hexano-6-Lactone) Fibers. Pure & Appl. Chem. vol. 69, No. 12, pp. 2567-2575, 1997. [cited by applicant]
Mochizuki et al. “Studies on Biodegradable Poly(Hexano-6-Lactone) Fibers. Part 2: Environmental Degradation”, Pure Appl. Chem., vol. 71, No. 11, pp. 2177-2188, 1999. [cited by applicant]
Molloy et al. D-11 Kinetic Studies of the Ring-Opening Bulk Polymerization of e-Caprolactone by Dilatometry (Session: Polymer/Wear), Journal of Solid Mechanics and Materials Engineering, vol. 1, No. 4, 2007, pp. 613-623. [cited by applicant]
Molloy, R., et al. “Factors influencing the small-scale melt spinning of poly (?-caprolactone) monofilament fibers”. Polymer International, vol. 52, issue 7, (Jun. 19, 2003), pp. 1175-1181. Retrieved from the internet, … [cited by applicant]
Scott et al. “Evaluation of a fully absorbable poly-4-hydroxybutyrate/absorbable barrier composite mesh in a porcine model of ventral hernia repair”, Surg.Endose (2016) 30:3691-3701. [cited by applicant]
Speranza et al. “Characterization of the Polycaprolactone Melt Crystallization: Complementary Optical Microscopy, DSC, and AFM Studies”, The Scientific World Journel, vol. 2014, Article ID 720157, 9 pgs. [cited by applicant]
Williams et al. “Poly-4-hydroxybutyrate (P4HB): a new generation of sesorbable medical devices for tissue repair and regeneration”, Biomedizinische Technik/Biomedical Engineering, Jun. 13. [cited by applicant]
F. Selli et al. Mesophase in melt-spun poly(ϵ-caprolactone) filaments: Structure-mechanical property relationship, Polymer, vol. 206 (Aug. 4, 2020), pp. 5, table 1,2,4, figure 1. [cited by applicant]